STAR.NS : Summary for STRIDES SHASUN LTD INR10 - Yahoo Finance

U.S. Markets open in 2 hrs 8 mins

Strides Shasun Limited (STAR.NS)


NSE - NSE Real Time Price. Currency in INR
Add to watchlist
1,076.35-15.45 (-1.42%)
At close: 3:29PM IST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close1,091.80
Open1,092.00
Bid0.00 x
Ask1,076.35 x
Day's Range1,070.00 - 1,100.00
52 Week Range918.00 - 1,274.70
Volume168,820
Avg. Volume298,390
Market Cap96.25B
BetaN/A
PE Ratio (TTM)21.03
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters3 years ago

    Gilead signs hepatitis C pact to cut drug cost for poor

    * Gilead plans to sell Sovaldi in India for $300 a month (Adds detail, background) Approximately 150 million people in the world live with chronic hepatitis C infection, most of them in low and middle-income countries, and the new licences are designed to give many of them access to an otherwise unaffordable drug. As with AIDS 15 years ago, modern drugs are transforming the ability to fight hepatitis C, and Sovaldi has been hailed as a breakthrough in treating the liver-destroying virus. Sovaldi, chemically known as sofosbuvir, is a far more effective and better-tolerated treatment than older injection regimens, but Gilead has come under fire over its U.S.

  • Reuters3 years ago

    Gilead licenses hepatitis C drug to Cipla, Ranbaxy, 5 others

    Cadila Healthcare, Mylan Laboratories Ltd, Sequent Scientific Ltd, Strides Arcolab Ltd and Hetero Drugs Ltd are the others who will now be able to make and sell the Sovaldi generic, the company said in a statement. The companies will be allowed to set their own prices for the generic drug, and will pay a royalty on their earned sales to Gilead, it said.

  • We're sorry this is all we were able to find about this topic.